Orchid exits Chinese JV on 'flat' prospects but API exports to continue
This article was originally published in Scrip
Executive Summary
Orchid Chemicals and Pharmaceuticals' recent exit from its 50:50 manufacturing joint venture in China does not imply that it is moving out of the Chinese market, the Indian company has affirmed. Orchid's plans are seen rather as part of the firm's strategy to consolidate manufacturing operations in India.